Immunex on Bristol/ImClone deal
Executive Summary
Bristol's agreement with ImClone to develop the anti-EGF antibody C225 "does serve to further validate this target and the importance of it for cancer patients," Immunex' Fritzky says. Immunex is co-developing a competing EGF-receptor antibody, ABX-EGF, with Abgenix. "At this stage...we just have to keep our eyes focused on our goal" and "move ahead through Phase II"